Health Care · Pharmaceutical Preparations

FHTX Foghorn Therapeutics Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 182246259 filings
Russell 2000

FHTX at a glance

Foghorn Therapeutics Inc. (FHTX, SEC CIK 1822462) filed its latest 10-K annual report on March 11, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and Form 4 insider filings as recently as June 25, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Foghorn Therapeutics Inc. (FHTX) reported revenue of $30.9 million (up 36.8% from FY2024) and a net loss of $74.3 million. Diluted EPS was -$1.18.
  • As of September 30, 2026, 23 institutional investment managers tracked by SignalX reported holding Foghorn Therapeutics Inc. (FHTX) shares worth $38.1 million in 13F-HR filings.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$30.9M
+36.8% vs prior year
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
23 funds
$38.1M · +0 vs prior quarter
Latest 8-K
Nov 9, 2026
Item 2.02 · Item 7.01

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Collaboration revenue $83.5M, up $75.4M YoY from $8.2M, including $74.1M cumulative catch-up adjustment
  • Operating margin 67.8% vs negative 226.9% YoY, with operating income $56.6M vs loss of $18.5M
  • Lilly partnered programs, largest R&D line, $4.6M, down $2.2M YoY; early development costs increased $1.7M
  • Cash, equivalents and marketable securities $156.2M; nine-month operating cash outflow $61.4M
  • Near-term cost reductions expected from pipeline reprioritization and 40% workforce reduction; cash runway expected at least twelve months

Risk Factors

  • New clinical-development risk: FHD-909 and SMARCA2 degrader halted after Phase 1 data review
  • New workforce-reduction risk: strategic reprioritization cut approximately an undisclosed percentage of employees
  • Regulatory risk: IRS audit opened for tax year 2023, with potential outcomes under evaluation
  • Financial risk: accumulated deficit $601.4 million despite $31.1 million nine-month net income
  • Collaboration concentration risk: $74.1 million revenue recognized from Lilly program reprioritization નિર્ણ

AI summary of the FHTX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 9, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 financial results for the quarter ended September 30, 2026 announced
  • Press release contains the substantive financial figures and operating updates

Item 7.01: Regulation FD Disclosure

  • November 2026 investor presentation furnished as Exhibit 99.2
  • Presentation likely contains updated company, pipeline, or strategic information for investor meetings

Item EX-99.1: Item EX-99.1

  • Q3 2026 collaboration revenue $83.5M vs $8.2M, including $74.1M cumulative catch-up from discontinued FHD-909 and SMARCA2 programs
  • Net income $58.2M, or $0.80 diluted EPS, vs $15.8M loss and $0.25 loss per share in Q3 2025

Item EX-99.2: Item EX-99.2

  • Investor presentation outlines wholly owned pipeline spanning oncology, I&I, and induced-proximity programs
  • Cash and equivalents $156.2M as of 09/30/2026, supporting runway into second half of 2029
Filed Oct 1, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • Foghorn will not advance FHD-909 into the clinical trial expansion phase
  • Strategic prioritization signals reduced development focus on FHD-909

Item 2.05: Costs Associated with Exit or Disposal Activities

  • FHD-909 Phase 1 will not advance to expansion after clinical-data review
  • Lilly collaboration activities no longer anticipated, removing a partnered development path

Item EX-99.1: Item EX-99.1

  • Foghorn and Lilly will not advance FHD-909 after Phase 1 data failed to demonstrate sufficient efficacy
  • Selective SMARCA2 degrader collaboration also ending, removing a partnered development path
Filed Aug 6, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Foghorn announced financial results for the quarter ended June 30, 2026
  • Results released August 6, 2026, with detailed figures in Exhibit 99.1

Item 7.01: Regulation FD Disclosure

  • August 2026 investor presentation, signaling updated corporate messaging for investor meetings
  • Exhibit 99.2 may contain material pipeline, clinical, financial, or strategic updates relevant to valuation

Item EX-99.1: Item EX-99.1

  • Q2 collaboration revenue $16.1M vs $7.6M, boosted by $14.2M cumulative catch-up tied to Lilly research-term expiration
  • Net loss narrowed to $7.2M from $17.9M, while R&D fell to $18.5M from $21.8M

AI summaries of FHTX 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for FHTX

Don't miss the next FHTX filing

  • Alerts as it files. A push when FHTX files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut FHTX, by share count.
  • Ask anything. An AI agent that reads every FHTX filing and answers with sources.

FHTX alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
SMITH IAN FAJun 24, 2026$4.08
Mendelsohn MichaelAJun 24, 2026$4.08
Cole Douglas G.AJun 24, 2026$4.08
PARSHALL B LYNNEAJun 24, 2026$4.08
Duty StuartAJun 24, 2026$4.08
Lynch Thomas J. Jr.AJun 24, 2026$4.08
Gallagher NeilAJun 24, 2026$4.08
Biller ScottAJun 24, 2026$4.08

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue$34.2M$22.6M$30.9M
Operating Income--$102.7M-$86.4M
Net Income-$98.4M-$86.6M-$74.3M
Op. Margin--454.3%-279.5%
Net Margin-288.2%-383.2%-240.3%
Balance Sheet
Total Assets-$284.0M$198.1M
Equity--$45.5M-$108.5M
ROE-190.3%68.5%
Per Share
EPS$-2.34$-1.58$-1.18
Cash Flow
Operating CF--$100.4M-$86.1M
CapEx$1.2M$906K$50K

Source: XBRL data in Foghorn Therapeutics Inc. (FHTX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate FHTX share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
FHTX shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202623$38.1M
Q2 202623$75.1M
Q1 202623$73.2M
Q4 202522$80.3M
Q3 202520$69.3M
Q2 202520$65.1M
Q1 202518$41.4M
Q4 202413$52.5M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 162 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

FHTX filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
10-QNov 9, 2026Analysis
8-KNov 9, 2026Analysis-
8-KOct 1, 2026Analysis-
10-QAug 6, 2026Analysis
8-KAug 6, 2026Analysis-
4Jun 25, 2026--
4Jun 25, 2026--
4Jun 25, 2026--
4Jun 25, 2026--
4Jun 25, 2026--
4Jun 25, 2026--
4Jun 25, 2026--
4Jun 25, 2026--
4Jun 25, 2026--
8-KJun 24, 2026Analysis-
10-QMay 7, 2026Analysis
8-KMay 7, 2026Analysis
8-KApr 21, 2026Analysis-
4Apr 13, 2026--
10-KMar 11, 2026-
8-KMar 11, 2026Analysis-
8-KFeb 23, 2026Analysis-
4Feb 6, 2026-
4Feb 2, 2026-
4Feb 2, 2026-

Related Health Care companies

All Health Care →

FHTX SEC filings: frequently asked questions

Which institutions hold FHTX stock?

As of September 30, 2026, the largest Foghorn Therapeutics Inc. (FHTX) holders among the 13F filers tracked by SignalX were BlackRock ($10.9 million), Raymond James Financial ($8.9 million), Vanguard Capital Management LLC ($5.7 million), State Street Corp ($2.5 million), JPMorgan Chase & Co ($2.3 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was FHTX's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Foghorn Therapeutics Inc. (FHTX) reported revenue of $30.9 million (up 36.8% from FY2024) and a net loss of $74.3 million. Diluted EPS was -$1.18. The figures come from the XBRL data in the 10-K.

What did FHTX report in its latest 8-K?

Foghorn Therapeutics Inc. (FHTX) filed an 8-K on November 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure). Q3 2026 financial results for the quarter ended September 30, 2026 announced.

What are the latest FHTX SEC filings?

Foghorn Therapeutics Inc. (FHTX) filed its latest 10-K annual report on March 11, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and a Form 4 insider filing on June 25, 2026.

What is FHTX's SEC CIK number?

Foghorn Therapeutics Inc. (FHTX)'s SEC Central Index Key (CIK) is 1822462. EDGAR lists every FHTX filing under that number.

Ask anything about FHTX

The research agent reads FHTX's filings, financials, insider trades and 13F holders, then answers with sources.